Compugen To Present New Insights into the Tumor Microenvironment Using Single Cell Spatial Transcriptomics at Keystone Symposium
Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company, will present insights on the immune-tumor microenvironment at the Keystone Symposium on Cancer Immunotherapy, scheduled for March 20-24, 2022, in British Columbia, Canada. The oral presentation is set for March 21, 2022, titled "Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics." A poster will also be presented on March 22, 2022, showcasing further findings. More details and the presentation will be available on Compugen's website.
- None.
- None.
HOLON, Israel, March 14, 2022 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it has been selected to give an oral presentation on exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics at the Keystone Symposium on Cancer Immunotherapy to take place on March 20-24, 2022, in British Columbia, Canada.
Presentation & poster details
Oral presentation date: Monday, March 21, 2022
Meeting title: Cancer Immunotherapy: Decoding the Cancer Immunity Interactome
Session title: Imaging Cancer Immunity
Presentation & poster title: Exploring the immune-tumor microenvironment using high resolution single-cell spatial transcriptomics
Poster date: Tuesday, March 22, 2022
Poster number: Poster #2041
The abstract is available on the publication section of Compugen's website www.cgen.com.
The presentation will be made available on Compugen's website www.cgen.com on March 21, 2022.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody, for the treatment of solid tumors, in Phase 1 as a single agent and in dual, and triple combinations; COM902, a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid and hematological tumors, undergoing Phase 1 studies as a single agent and in dual combination with COM701. Partnered programs include an antibody targeting ILDR2 in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2939) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company Contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-present-new-insights-into-the-tumor-microenvironment-using-single-cell-spatial-transcriptomics-at-keystone-symposium-301501660.html
SOURCE Compugen Ltd.
FAQ
When is Compugen's presentation at the Keystone Symposium 2022?
What will Compugen present at the Keystone Symposium?
When is Compugen's poster presentation scheduled?
Where is the Keystone Symposium being held?
What is the significance of the Keystone Symposium for CGEN?
